The National Health Insurance Authority (NHIA) has announced that hospitals would be paid 30% more for medicines and services under the scheme.
This comes after the National Health Insurance Act 852 (Act 2012), which focused on tariffs became operational on July 1, 2022.
“The NHIA Board commissioned a multi-stakeholder team to conduct a costing exercise of healthcare services that would inform the next service tariff review. The output of the costing exercise was used to determine reviewed tariff rates.”
“In line with standard practice, all key stakeholders were involved in the process of review. The average impact of the service tariffs, across all provider types in the public sector, is about a 35% increment from the previous service tariffs”, said a statement signed by the NHIA Chief Executive, Dr. Bernard Okoe Boye.
He added that these adjustments have been made in consultation with all stakeholders, taking into consideration all economic indices.
In his view, the considerations will improve the availability of all medicines on the NHIS medicine list nationwide and further minimize out-of-pocket payments (Unauthorized fees) charged to NHIS members at the point of healthcare delivery and increase the public’s confidence in the Scheme.
“The reviewed medicines and tariffs include treatment of the newly added four Childhood Cancers, Clinical Family Planning services, Hydroxyurea for Sickle Cell Anaemia, and other new formulations, and take effect from July 1st, 2022”, said the statement.
Below is the full statement:
